SSG XVIII/AIO 试验：结果改变了胃肠道间质瘤当前的辅助治疗推荐。
The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.
机构信息
Department of Surgery, Section of Surgical Oncology, Geisel School of Medicine at Dartmouth Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
出版信息
Am J Clin Oncol. 2013 Feb;36(1):89-90. doi: 10.1097/COC.0b013e31827a7f55.
Although adjuvant imatinib (IM) for high risk GIST is an accepted treatment consideration, the duration of therapy remains controversial. The recently published SSGXVIII/AIO randomized clinical trial of 3 years vs. 1 year of adjuvant IM has established a benefit of RFS and OS for the 3 year cohort. Future studies are necessary to continue to further delineate risk variables for GIST recurrence.
虽然辅助伊马替尼（IM）治疗高危 GIST 是一种被接受的治疗方案，但治疗持续时间仍存在争议。最近发表的 SSGXVIII/AIO 随机临床试验比较了 3 年与 1 年辅助 IM 治疗，结果显示 3 年组在 RFS 和 OS 方面具有获益。需要进一步开展研究，以明确 GIST 复发的风险变量。
Zotero 插件